Gene Expression Profiling for Bronchial Lesion Subtyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and treating bronchial premalignant lesions are invasive, moderately sensitive, and lack tools to identify which lesions will progress to cancer, with no effective non-surgical treatments available.
Innovation Solution
Development of tests and methods using gene expression profiles to identify specific molecular subtypes of bronchial premalignant lesions, allowing for targeted therapeutic regimens including bronchoscopy, chest CT scans, and administration of anti-proliferative or immune-stimulating drugs based on gene expression levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Difficulty of detecting and measuring
If bronchoscopy-based procedures are used to survey the central airway, then detection capability is improved, but invasiveness increases and patient comfort deteriorates
Solution Approach 1:
The patent replaces mechanical bronchoscopy procedures with a molecular detection system using gene expression profiles. By analyzing molecular signatures (gene modules) from easily obtainable samples, the system achieves accurate detection without requiring invasive mechanical insertion of bronchoscopes into the airway
Solution Approach 2:
The patent introduces molecular biomarkers (gene expression profiles) as intermediaries to detect bronchial premalignant lesions. Instead of directly visualizing lesions through invasive bronchoscopy, the system uses molecular signatures as mediators that can be detected from less invasive samples, thereby maintaining detection accuracy while reducing procedural invasiveness
2Device complexity
If current detection methods are used, then procedure simplicity is maintained, but detection sensitivity and specificity worsen
Solution Approach 1:
The patent changes the detection parameter from visual appearance (which has limited precision) to molecular gene expression profiles (which provide high precision). By measuring specific gene module expressions, the system achieves superior sensitivity and specificity while maintaining procedural simplicity through standardized molecular testing protocols
3Reliability
If all bronchial premalignant lesions are treated with surgery or bronchoscopy, then treatment completeness is improved, but treatment invasiveness worsens
Solution Approach 1:
The patent applies local quality by tailoring treatment to the specific molecular subtype of each lesion. Instead of uniform invasive treatment for all lesions, the system identifies distinct molecular subtypes (e.g., proliferative vs. non-proliferative gene expression profiles) and applies appropriate treatment intensity, reducing invasiveness for low-risk subtypes while maintaining completeness for high-risk subtypes
Solution Approach 2:
The patent performs preliminary molecular characterization of lesions before determining treatment approach. By analyzing gene expression profiles in advance, the system can identify which lesions require aggressive intervention and which can be monitored or treated with less invasive methods, thereby reducing overall treatment invasiveness while maintaining completeness
4Ease of operation
If no molecular subtyping is performed, then treatment uniformity is maintained, but treatment effectiveness worsens
Solution Approach 1:
The patent segments bronchial premalignant lesions into distinct molecular subtypes based on gene expression profiles. By dividing the heterogeneous population of lesions into molecular categories (such as proliferative vs. non-proliferative subtypes), the system enables targeted treatment strategies for each subtype, thereby improving treatment effectiveness while maintaining operational feasibility through standardized molecular classification
Data Source
AI summary
The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.